CytomX outlines cancer strategy. CytomX Therapeutics stock trades ahead of November 5 results

Published on 10/05/2026 at 14:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was USD 1.42 million versus USD 12.39 million. CytomX Therapeutics stock costs EUR 2.29 versus EUR 2.27, a 0.88 percent change on October 5, 2026.

CTMX, US23284F1057, Illustration mit AI erstellt.

CytomX Therapeutics (ISIN US23284F1057) was trading at EUR 2.29 at Lang & Schwarz on October 5, 2026 at 1:59 p.m. CEST, plus 0.88 percent versus the prior close of EUR 2.27. At a September 14, 2026 healthcare conference, CytomX outlined a two-track oncology strategy centered on its masked biologics platform, as Investing.com reported.

Cash runway supports clinical plans

According to Investing.com on September 14, 2026, CytomX had USD 330.00 million in cash as of June 30, 2026. An expanded Regeneron collaboration added USD 37.00 million in July, lifting pro forma cash to USD 367.00 million and extending the planned runway into the second half of 2028.

The cash position gives the company room to fund registrational work, combination studies and expansion of Varseta-M, its lead EpCAM-targeted antibody-drug conjugate. The program is being developed for late-line metastatic colorectal cancer, while CytomX also advances a masked interferon program in melanoma.

Revenue miss remains the counterweight

The latest reported quarter was more difficult financially. MarketBeat reported that second-quarter 2026 revenue was USD 1.42 million versus USD 12.39 million expected, while the company posted a loss of USD 0.09 per share against a USD 0.08 consensus loss.

The comparison shows the central tension in the stock. CytomX had cash to finance development, but its second-quarter revenue was 88.54 percent below the cited consensus forecast. The finance data also show a second-quarter 2026 net loss of USD 20.67 million and operating loss of USD 23.78 million.

Targets remain above the share price

MarketBeat reported on September 27, 2026 that twelve analysts gave CytomX an average Moderate Buy rating and an average 12-month price target of USD 11.90. The same report said JPMorgan cut its target from USD 12.00 to USD 11.00 on August 13, 2026, while Guggenheim reduced its target from USD 15.00 to USD 14.00 on August 10, 2026.

Those targets are stated in US dollars and are not compared with the euro reference price. The separate market snapshot showed a USD 2.55 to USD 8.21 52-week range and a USD 557.3 million market capitalization as of October 2, 2026.

CTMX price holds near EUR 2.30

CytomX was trading at EUR 2.29 at Lang & Schwarz on October 5, 2026 at 1:59 p.m. CEST, plus 0.88 percent versus the prior close of EUR 2.27. Its primary listing is Nasdaq, where the company trades under CTMX.